ATE386545T1 - Wachstumsfaktor-modifizierte proteinmatrizes zur geweberekonstruktion (tissue engineering) - Google Patents

Wachstumsfaktor-modifizierte proteinmatrizes zur geweberekonstruktion (tissue engineering)

Info

Publication number
ATE386545T1
ATE386545T1 AT02792510T AT02792510T ATE386545T1 AT E386545 T1 ATE386545 T1 AT E386545T1 AT 02792510 T AT02792510 T AT 02792510T AT 02792510 T AT02792510 T AT 02792510T AT E386545 T1 ATE386545 T1 AT E386545T1
Authority
AT
Austria
Prior art keywords
matrix
heparin
drug
protein
regeneration
Prior art date
Application number
AT02792510T
Other languages
German (de)
English (en)
Inventor
Jeffrey Hubbell
Matthias Lutolf
Jason Schense
Anna Jen
Original Assignee
Eth Zuerich
Univ Zuerich
Hubbell Jeffrey A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/024,918 external-priority patent/US20020168718A1/en
Priority claimed from PCT/EP2002/012458 external-priority patent/WO2003040235A1/en
Priority claimed from US10/323,046 external-priority patent/US7601685B2/en
Application filed by Eth Zuerich, Univ Zuerich, Hubbell Jeffrey A filed Critical Eth Zuerich
Application granted granted Critical
Publication of ATE386545T1 publication Critical patent/ATE386545T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/225—Fibrin; Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT02792510T 2001-12-18 2002-12-18 Wachstumsfaktor-modifizierte proteinmatrizes zur geweberekonstruktion (tissue engineering) ATE386545T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/024,918 US20020168718A1 (en) 1997-04-03 2001-12-18 Enzyme-mediated modification of fibrin for tissue engineering
PCT/EP2002/012458 WO2003040235A1 (en) 2001-11-07 2002-11-07 Synthetic matrix for controlled cell ingrowth and tissue regeneration
US10/323,046 US7601685B2 (en) 1998-08-27 2002-12-17 Growth factor modified protein matrices for tissue engineering

Publications (1)

Publication Number Publication Date
ATE386545T1 true ATE386545T1 (de) 2008-03-15

Family

ID=27807134

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02792510T ATE386545T1 (de) 2001-12-18 2002-12-18 Wachstumsfaktor-modifizierte proteinmatrizes zur geweberekonstruktion (tissue engineering)

Country Status (9)

Country Link
JP (2) JP4560291B2 (es)
AT (1) ATE386545T1 (es)
AU (2) AU2002358272B2 (es)
BR (1) BRPI0215192B8 (es)
CA (1) CA2470419A1 (es)
DE (1) DE60225185T2 (es)
ES (1) ES2301697T3 (es)
MX (1) MXPA04006021A (es)
WO (1) WO2003052091A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351423B2 (en) 2004-09-01 2008-04-01 Depuy Spine, Inc. Musculo-skeletal implant having a bioactive gradient
WO2006064381A2 (en) * 2004-12-10 2006-06-22 Straumann Holding Ag Protein formulation
EP1862170B1 (en) 2004-12-10 2012-03-14 Straumann Holding AG Enamel formulation with amelogenin
SE0403014D0 (sv) 2004-12-10 2004-12-10 Straumann Holding Ag New protein formulation
EP1828244A2 (en) * 2004-12-22 2007-09-05 Kuros Biosurgery AG Michael-type addition reaction functionalised peg hydrogels with factor xiiia incorporated biofactors
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
WO2006073711A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
BRPI0606409A2 (pt) 2005-01-06 2009-06-23 Kuros Biosurgery Ag matrizes suplementadas para o reparo de fraturas ósseas
ES2675174T3 (es) 2007-04-09 2018-07-09 The Board Of Trustees Of The University Of Arkansas Proteínas de fusión de un dominio de enlazamiento a colágeno y hormona paratiroidea
EP2136850B1 (en) 2007-04-13 2012-02-01 Kuros Biosurgery AG Polymeric tissue sealant
WO2009047361A2 (en) * 2007-10-12 2009-04-16 Kuros Biosurgery Ag Injectable fibrin compositions for tissue augmentation comprising strontium salt
CA2721477A1 (en) 2008-04-18 2009-12-03 Kuros Biosurgery Ag Dispensing device, kit containing the device, and method of operating the device
WO2011025957A2 (en) * 2009-08-28 2011-03-03 Ecole Polytechnique Federal De Lausanne Tg-aprotinin fusion proteins and matrices thereof
KR101922741B1 (ko) * 2011-02-03 2019-02-20 노스이스턴 유니버시티 생물학적 물질의 고도로 특이적인 포획 및 방출을 위한 방법 및 조성물
WO2012123028A1 (en) 2011-03-16 2012-09-20 Kuros Biosurgery Ag Pharmaceutical formulation for use in spinal fusion
WO2013120060A1 (en) 2012-02-09 2013-08-15 The Board Of Trustees Of The University Of Arkansas Delivery of therapeutic agents by a collagen binding protein
EP3391899B1 (en) 2011-12-14 2020-07-15 The Board of Trustees of the University of Arkansas Delivery of therapeutic agents by a collagen binding protein
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
US9421245B2 (en) * 2012-06-25 2016-08-23 The Brigham And Women's Hospital, Inc. Targeted therapeutics
WO2017042301A1 (en) * 2015-09-09 2017-03-16 ETH Zürich Injectable macroporous hydrogels
WO2018148573A1 (en) 2017-02-10 2018-08-16 The Board Of Trustees Of The University Of Arkansas Collagen-binding agent compositions and methods of using the same
EP3536353A1 (en) 2018-03-09 2019-09-11 Kuros Biosurgery AG Method and kits for producing a fibrin matrix
US12403179B2 (en) 2021-02-18 2025-09-02 The Board Of Trustees Of The University Of Arkansas Release of growth factors at wound healing stages

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171670A (en) * 1989-05-12 1992-12-15 The General Hospital Corporation Recombinant dna method for production of parathyroid hormone
US5589452A (en) * 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
JP2000500019A (ja) * 1995-11-16 2000-01-11 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング ストレプトアビジン融合タンパク質経由でのペプチドの生産方法
WO1999031137A1 (en) * 1997-12-18 1999-06-24 Eli Lilly And Company Crystalline teriparatide
CA2359318C (en) * 1999-02-01 2009-06-30 Universitat Zurich Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups
JP2001190280A (ja) * 1999-02-19 2001-07-17 Terumo Corp コラーゲン結合性生理活性ポリペプチド

Also Published As

Publication number Publication date
JP4560291B2 (ja) 2010-10-13
AU2002358272A1 (en) 2003-06-30
DE60225185T2 (de) 2009-02-19
JP2005517658A (ja) 2005-06-16
WO2003052091A8 (en) 2003-08-07
MXPA04006021A (es) 2005-08-19
ES2301697T3 (es) 2008-07-01
JP2009102383A (ja) 2009-05-14
AU2009201588A1 (en) 2009-05-14
DE60225185D1 (de) 2008-04-03
BR0215192A (pt) 2005-04-26
BRPI0215192B1 (pt) 2016-03-22
AU2009201588B2 (en) 2011-02-24
CA2470419A1 (en) 2003-06-26
WO2003052091A1 (en) 2003-06-26
BRPI0215192B8 (pt) 2021-07-27
AU2002358272B2 (en) 2009-01-22

Similar Documents

Publication Publication Date Title
DE60225185D1 (de) Wachstumsfaktor-modifizierte proteinmatrizes zur geweberekonstruktion (tissue engineering)
MXPA02010758A (es) Matrices de proteina modificada con factor de crecimiento para tejido producido por ingenieria.
Kim et al. Shear-induced alignment of collagen fibrils using 3D cell printing for corneal stroma tissue engineering
Seliktar Extracellular stimulation in tissue engineering
Nillesen et al. Increased angiogenesis and blood vessel maturation in acellular collagen–heparin scaffolds containing both FGF2 and VEGF
Place et al. Strontium-and zinc-alginate hydrogels for bone tissue engineering
Lin et al. Thiol–norbornene photoclick hydrogels for tissue engineering applications
Thomopoulos et al. Enhanced flexor tendon healing through controlled delivery of PDGF‐BB
Tsuji et al. BMP4 is dispensable for skeletogenesis and fracture-healing in the limb
Kearney et al. Macroscale delivery systems for molecular and cellular payloads
Freudenberg et al. A star-PEG–heparin hydrogel platform to aid cell replacement therapies for neurodegenerative diseases
Hao et al. Collagen/heparin bi‐affinity multilayer modified collagen scaffolds for controlled bFGF release to improve angiogenesis in vivo
Ramburrun et al. A review of bioactive release from nerve conduits as a neurotherapeutic strategy for neuronal growth in peripheral nerve injury
KR970704481A (ko) 생인공성 외세포성 매트릭스용 조성물 및 방법(compositions and methods for a bioartificial extracellular matrix)
Dawson et al. The periosteal requirement and temporal dynamics of BMP2‐induced middle phalanx regeneration in the adult mouse
DE60334224D1 (de) Zusammensetzung für die herstellung zellkompatibler, injizierbarer, selbstgelierender chitosan lösungen zum einkapseln und verabreichen von lebenden zellen oderbiologisch aktiven faktoren
WO2010060104A3 (en) Implantable liposome embedded matrix composition, uses thereof, and polycaprolactone praticles as scaffolds for tissue regeneration
Draenert et al. BMP‐2 and bFGF release and in vitro effect on human osteoblasts after adsorption to bone grafts and biomaterials
CA2728939C (en) Heparin-conjugated fibrin gel and method and kit for preparing the same
DE60140200D1 (de) Ex vivo verfahren und zusammensetzungen zur nukleinsäureverabreichung
US20180140742A1 (en) Graft material for nerve regeneration, method for producing graft material for nerve regeneration, and kit for producing graft material for nerve regeneration
Song et al. Sustained delivery of biomolecules from gelatin carriers for applications in bone regeneration
Park et al. Enhancement of the osteogenic efficacy of osteoblast transplantation by the sustained delivery of basic fibroblast growth factor
Galas Jr et al. Surface density of vascular endothelial growth factor modulates endothelial proliferation and differentiation
Han et al. Optimal delivery systems for bone morphogenetic proteins in orthopedic applications should model initial tissue repair structures by using a heparin-incorporated fibrin–fibronectin matrix

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties